Rezolute Inc. (NASDAQ: RZLT) announced that its Phase 3 sunRIZE study evaluating ersodetug for congenital hyperinsulinism did not meet its ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE